Clinical Trials Logo

Clinical Trial Summary

Transcutaneous Afferent Vagus Nerve Stimulation [taVNS] is used to modulate persistent & intense desire control amongst a specific participant group. Testing Center Order of Deliver Number


Clinical Trial Description

taVNS Diagnostic Spectrum Testing Center Order of Delivery 1. - Addiction - Opioid 2. - Chronic Pain - Central 3. - Anxiety + Panic Disorder 4. - MDD - Major Depression Disorder 5. - Addiction - Nicotine 6. - ADHD 7. - Addiction - Stimulant 8. - Addiction - Sexual + Love 9. - Addiction - Paraphilia 10. - Parkinsons 11. - Immune Enhancing 12. - Addiction - Overeating RE-ORDERED CLINICAL TRIAL - NINE Physiologic effects of taVNS stimulation have been extensively researched for over 150 years. Drug-resistant depression (MDD), migraine headaches, pelvic pain modulation, facilitation of motor learning in neonates, post stroke rehabilitation and seizures are some of the conditions investigated with favorable results using taVNS intervention. taVNS physiologic & mental effects have been noted to have advantageous therapeutic results on a vast diagnostic spectrum. A clinical testing program for pre- and post-test was devised as a means to identify & measure treatment effects in specific T3, 4 and early 5 (Tanner) sub-group visual stimulation. The programmatic (software) of the stimulation medium created for this study is aimed to abate the use of a phallometric device purposed to measure sexual stimulation effects on participants. Great effort has been assigned for the preservation of visual data to be shared in the investigators' research centre with other researchers internationally. The participant testing platform created for this study allows for a full-proof research ethics anonymous & confidential registry & testing process (triple blind). Aggressive optimum (supra-threshold and below-pain threshold) taVNS is the therapeutic modality of choice in order to examine desire down-regulation effects using taVNS. DSM-V stock participants must be sub-grouped in the paraphilic categorical structure of the DSM-V. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05482412
Study type Interventional
Source American University Of Montserrat
Contact Michel R Rice, MD [AUM]
Phone 14165588601
Email drrice@bettercalldoc.ca
Status Not yet recruiting
Phase N/A
Start date September 15, 2023
Completion date December 15, 2024

See also
  Status Clinical Trial Phase
Not yet recruiting NCT04316650 - Study of Maintenance of the Efficiency and Adverse Effects of Pharmacological Treatments in Sex Offenders With Paraphilia N/A
Completed NCT01743209 - Descriptive Epidemiology Study for Patients With Paraphilia Sex Offenders and Receiving Androgen Antagonists N/A
Terminated NCT00379626 - Cognitive and Hormonal Treatment of Sex Offenders Phase 1